Clinical trial
A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)
NCT02808104 is registered in ClinicalTrials.gov with NLS Pharmaceutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)
- Lead sponsor
- NLS Pharmaceutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2016
- Completion date
- March 28, 2017
- Enrollment
- 84 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.